Healthcare Medtech

Abbott $44.3 billion is the whole company. Medtronic $36.4 billion is FY26 (ended April 24, 2026). Stryker $25.1 billion, Boston Scientific $20.1 billion, and GE HealthCare $20.6 billion are calendar 2025. Intuitive $10.1 billion and Edwards $6.1 billion are the robotics and structural-heart specialists.

2025: Medical Devices $21.39 billion, Diagnostics $8.94 billion, Nutrition $8.45 billion, Established Pharmaceuticals $5.54 billion. Devices grew 12.6 percent. Diagnostics fell 4.3 percent as COVID testing dropped to $297 million from $747 million.

FY26: Cardiovascular $13.976 billion, Neuroscience $10.287 billion, Medical Surgical $8.815 billion, Diabetes $3.112 billion. Diabetes is the MiniMed carve-out candidate, not the core hospital franchise.

2025: MedSurg and Neurotechnology $15.65 billion, Orthopaedics $9.47 billion. Those two lines are the whole company. Implant and capital sales, not hospital admissions.

2025: Cardiovascular $13.25 billion. Endoscopy $2.92 billion, Urology $2.71 billion, Neuromodulation $1.20 billion. Those four lines are net sales of $20.07 billion. MedSurg as a subtotal was $6.82 billion.

2025: Imaging $9.25 billion, Advanced Visualization Solutions $5.35 billion, Patient Care Solutions $3.09 billion, Pharmaceutical Diagnostics $2.90 billion. PDx grew 15.6 percent. PCS declined 1.2 percent.

2025: instruments and accessories $6.02 billion, systems $2.47 billion, services $1.57 billion. About 3.15 million da Vinci procedures, up 18 percent. The razor is the procedure, not the robot placement.

2025 continuing ops after the Critical Care sale: TAVR $4.49 billion, Surgical Structural Heart $1.03 billion, TMTT $551 million. TMTT grew 56 percent and is still a $0.6 billion line.